DK1608362T3 - Stabiliseret farmaceutisk præparat indeholdende en amorf aktiv forbindelse - Google Patents

Stabiliseret farmaceutisk præparat indeholdende en amorf aktiv forbindelse

Info

Publication number
DK1608362T3
DK1608362T3 DK03770970T DK03770970T DK1608362T3 DK 1608362 T3 DK1608362 T3 DK 1608362T3 DK 03770970 T DK03770970 T DK 03770970T DK 03770970 T DK03770970 T DK 03770970T DK 1608362 T3 DK1608362 T3 DK 1608362T3
Authority
DK
Denmark
Prior art keywords
pharmaceutical composition
composition containing
active compound
stabilized pharmaceutical
amorphous active
Prior art date
Application number
DK03770970T
Other languages
English (en)
Inventor
Andrej Bastarda
Mateja Salobir
Rok Grahek
Original Assignee
Lek Tovarna Farmacevtskih
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32091984&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1608362(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lek Tovarna Farmacevtskih filed Critical Lek Tovarna Farmacevtskih
Application granted granted Critical
Publication of DK1608362T3 publication Critical patent/DK1608362T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK03770970T 2002-10-11 2003-10-10 Stabiliseret farmaceutisk præparat indeholdende en amorf aktiv forbindelse DK1608362T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI200200244A SI21302A (sl) 2002-10-11 2002-10-11 Stabiliziran farmacevtski izdelek z amorfno aktivno učinkovino
PCT/EP2003/011265 WO2004032920A1 (en) 2002-10-11 2003-10-10 Stabilized pharmaceutical preparation comprising an amorphous active substance

Publications (1)

Publication Number Publication Date
DK1608362T3 true DK1608362T3 (da) 2007-05-14

Family

ID=32091984

Family Applications (2)

Application Number Title Priority Date Filing Date
DK03770970T DK1608362T3 (da) 2002-10-11 2003-10-10 Stabiliseret farmaceutisk præparat indeholdende en amorf aktiv forbindelse
DK200700025U DK200700025U4 (da) 2002-10-11 2007-01-25 Stabiliseret farmaceutisk præparat indeholdende en amorf aktiv forbindelse

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK200700025U DK200700025U4 (da) 2002-10-11 2007-01-25 Stabiliseret farmaceutisk præparat indeholdende en amorf aktiv forbindelse

Country Status (21)

Country Link
US (2) US20040077708A1 (da)
EP (1) EP1608362B1 (da)
CN (1) CN100372529C (da)
AR (1) AR041588A1 (da)
AT (2) ATE354362T1 (da)
AU (1) AU2003280361B2 (da)
CY (1) CY1106608T1 (da)
CZ (1) CZ17610U1 (da)
DE (2) DE20321455U1 (da)
DK (2) DK1608362T3 (da)
ES (1) ES2285205T3 (da)
FI (1) FI7617U1 (da)
ME (1) ME00514B (da)
PT (1) PT1608362E (da)
RS (1) RS51819B (da)
RU (1) RU2358727C2 (da)
SI (2) SI21302A (da)
SK (1) SK5233Y1 (da)
TW (1) TWI320709B (da)
UA (1) UA85544C2 (da)
WO (1) WO2004032920A1 (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI20109A (sl) * 1998-12-16 2000-06-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Stabilna farmacevtska formulacija
US7411075B1 (en) * 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US7501450B2 (en) 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
JP4739672B2 (ja) 2001-12-21 2011-08-03 ネクター セラピューティクス 湿気のバリアを有するカプセルパッケージ
WO2005011638A2 (en) * 2003-08-05 2005-02-10 Zentiva, A. S. Methods for the stabilization of atorvastatin
DK1727795T3 (da) 2004-03-17 2012-04-16 Ranbaxy Lab Ltd Fremgangsmåde til fremstillingen af atorvastatin-calcium i amorf form
CA2573969C (en) * 2004-07-16 2014-02-04 Lek Pharmaceuticals D.D. Oxidative degradation products of atorvastatin calcium
KR20070106680A (ko) * 2004-09-30 2007-11-05 닥터 레디스 레보러터리즈 리미티드 비정질 아토르바스타틴 칼슘
CA2589537A1 (en) * 2004-12-02 2006-06-08 Stephen Craig Dyar Pharmaceutical compositions of amorphous atorvastatin and process for preparing same
TWI318571B (en) * 2005-06-10 2009-12-21 Lilly Co Eli Formulation of a thienopyridine platelet aggregation inhibitor
US20090216029A1 (en) * 2005-09-16 2009-08-27 Yatendra Kumar Process for the production of atorvastatin calcium in amorphous form
CA2547216A1 (en) 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
US20090247603A1 (en) 2005-12-23 2009-10-01 Orbus Pharma, Inc. Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor
EP1810667A1 (en) * 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
GB2450117A (en) * 2007-06-13 2008-12-17 Reckitt Benckiser Healthcare A water- and oxygen-occlusive blister tablet pack
KR20100051667A (ko) * 2007-07-27 2010-05-17 씨아이피엘에이 엘티디. 약제학적 조성물 및 그의 제조방법
US20090071855A1 (en) * 2007-09-14 2009-03-19 Bahuguna Sumit Packaging for amorphous statins and compositions thereof
EP2127628A1 (en) * 2008-05-27 2009-12-02 Ranbaxy Laboratories Limited Unit dose pack
EP2522348B1 (en) 2009-12-25 2016-05-25 Sawai Pharmaceutical Co., Ltd. Atorvastatin-containing coated preparation
EP2779999A2 (en) 2011-11-15 2014-09-24 Dr. Reddy's Laboratories Ltd. Pharmaceutical formulations comprising atorvastatin and glimepiride
CN102525942A (zh) * 2012-01-05 2012-07-04 金陵药业股份有限公司 一种阿托伐他汀钙肠溶微丸及其制备方法
CN107530311A (zh) * 2015-02-03 2018-01-02 卡德门制药有限公司 稳定的曲恩汀制剂
US10905113B2 (en) 2015-11-12 2021-02-02 Regents Of The University Of Minnesota Compositions and method for storing liquid biospecimens
EP3184103A1 (en) 2015-12-21 2017-06-28 Hexal AG Pharmaceutical composition comprising atorvastatin or a salt thereof
US11968975B2 (en) 2019-04-30 2024-04-30 Regents Of The University Of Minnesota Compositions and methods for storing liquid biospecimens

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2194418B2 (da) * 1971-08-02 1977-01-28 Sada Pietro
DE2625164A1 (de) * 1976-06-04 1977-12-15 Goedecke Ag Fluessige oder halbfeste arzneiformen oder kosmetische zubereitungen
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
CA2201354A1 (en) * 1994-09-30 1996-04-11 Becton, Dickinson And Company Method for forming and packaging iontophoretic drug delivery patches and the like to increase stability and shelf-life
GB9425783D0 (en) * 1994-12-21 1995-02-22 Ethical Pharma Ltd Packaging of patches
HRP960313B1 (en) * 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
US6087511A (en) * 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
SG125044A1 (en) * 1996-10-14 2006-09-29 Mitsubishi Gas Chemical Co Oxygen absorption composition
US6155454A (en) * 1997-05-03 2000-12-05 Donald C. George Pill dispenser employing a sealed pill carrier and integrated dispensing plungers
US6407278B2 (en) * 1998-11-16 2002-06-18 Medimmune Oncology, Inc. Stable amorphous amifostine compositions and methods for the preparation and use of the same
US6375956B1 (en) * 1999-07-22 2002-04-23 Drugtech Corporation Strip pack
EP1296672B2 (en) * 2000-06-09 2018-10-24 LEK Pharmaceuticals d.d. Stable pharmaceutical product and formulation
US6293393B1 (en) * 2000-07-18 2001-09-25 Sdk Co., Inc. Apparatus and methods for packaging and distributing combinations of foods and beverages
SI20848A (sl) * 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
EP1241110A1 (en) * 2001-03-16 2002-09-18 Pfizer Products Inc. Dispensing unit for oxygen-sensitive drugs

Also Published As

Publication number Publication date
RS51819B (sr) 2011-12-31
PT1608362E (pt) 2007-05-31
AU2003280361A1 (en) 2004-05-04
RS20050273A (en) 2007-06-04
FI7617U1 (fi) 2007-09-28
DK200700025U4 (da) 2008-03-14
AR041588A1 (es) 2005-05-26
CN100372529C (zh) 2008-03-05
SI21302A (sl) 2004-04-30
SK5233Y1 (en) 2009-09-07
DK200700025U1 (da) 2007-06-08
ME00514B (me) 2011-10-10
SI1608362T1 (sl) 2007-12-31
SK50062007U1 (en) 2009-03-05
WO2004032920A1 (en) 2004-04-22
DE60312049T2 (de) 2007-10-04
TW200501947A (en) 2005-01-16
ES2285205T3 (es) 2007-11-16
EP1608362B1 (en) 2007-02-21
CY1106608T1 (el) 2012-01-25
EP1608362A1 (en) 2005-12-28
US20090012150A1 (en) 2009-01-08
DE20321455U1 (de) 2007-05-24
CZ17610U1 (cs) 2007-06-18
RU2358727C2 (ru) 2009-06-20
DE60312049D1 (de) 2007-04-05
UA85544C2 (ru) 2009-02-10
AU2003280361B2 (en) 2009-02-26
RU2005114485A (ru) 2006-01-27
ATE354362T1 (de) 2007-03-15
AT10424U1 (de) 2009-03-15
FIU20070036U0 (fi) 2007-01-26
TWI320709B (en) 2010-02-21
US20040077708A1 (en) 2004-04-22
CN1703215A (zh) 2005-11-30

Similar Documents

Publication Publication Date Title
DK1608362T3 (da) Stabiliseret farmaceutisk præparat indeholdende en amorf aktiv forbindelse
CY2016042I2 (el) Νεες ετεροκυκλικες ενωσεις δραστικες ως αναστολεις των βητα-λακταμασων
DK1660104T3 (da) Farmaceutisk formulering indeholdende lanthanforbindelser
DE50309032D1 (de) Fungizide wirkstoffkombinationen
PT1501534E (pt) Formulacoes farmaceuticas
IL162118A0 (en) Pharmaceutical compositions containing an orally active taxane derivative
DE60317967D1 (de) Umhüllte feste Darreichungsform
DK1558585T3 (da) Neurologisk aktive forbindelser
PT1467724E (pt) Composicao farmaceutica orodispersavel de agomelatina
EP1631239A4 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING ACTIVE COMPOUNDS OF VITAMIN D
DK1624869T3 (da) Doseringsform indeholdende pantoprazol som aktiv bestanddel
PT1558263E (pt) Composicao farmaceutica de libertacao prolongada
FI20031078A0 (fi) Antibioottisesti oletiivisia farmaseuttisia koostumuksia
DK1666473T3 (da) Carboxylsyreforbindelser og medicinske sammensætninger indeholdende samme som aktiv ingrediens
ITFI20020144A1 (it) Formulazioni topiche stabilizzate contenenti ketoprofene.
ITTO20020672A0 (it) Composizioni farmaceutiche contenenti cheto-acidi per somministrazione endoperitoneale
DE502004003170D1 (de) Schmelzformulierte, multipartikuläre orale darreichungsform enthaltend clavulansäure
IL172304A0 (en) Pharmaceutical compositions comprising active vitamin d compounds
AU2003238896A1 (en) Stabilized pharmaceutical compositions containing benzimidazole compounds
ITMI20011457A0 (it) Composizione farmaceutica a rilascio modificato contenente bupropionehc1 come sostanza attiva
NO20044164L (no) Farmasoytiske sammensetninger
AU2003240741A1 (en) Calixarenes for use as excipient for an active substance
ITMI20020639A1 (it) Composizioni farmaceutiche comprendenti come principio attivo 1-isopropil-3°(4-m-toluidino-3-pridil)sulfonil!-urea
SE0200449D0 (sv) Pharmaceutical formulation
SE0201660D0 (sv) Pharmaceutical formulation